Multimodal Therapeutic Exercises and Their Role in Mitigating Chemotherapy-Induced Peripheral Neuropathy: A Longitudinal Study on Patient Outcomes

多模式治疗性运动及其在缓解化疗引起的周围神经病变中的作用:一项关于患者预后的纵向研究

阅读:1

Abstract

Introduction A common side effect post chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this study was to investigate the effect of a multimodal exercise program compared to standard physical therapy in treating CIPN symptoms and improving daily living skills. Aim The aim of this study was to evaluate the effect of multimodal therapeutic exercises and their role in mitigating CIPN symptoms on the neuropathy score and instrumental activities of daily living. Methodology Seventy-eight participants were divided into two groups: multimodal exercise program (Group A) and standard physical therapy (Group B) who fulfilled the inclusion criteria of age 25-55 years with CIPN (grade 2 or 3). Pre- and post-assessment was done using the modified Total Neuropathy Score (mTNS) and Lawton Instrumental Activities of Daily Living Scale (L-IADL). Results A significant improvement in the mTNS was seen in Group A (14.68 ± 1.66 to 7.03 ± 1.49, p<0.0001) compared to Group B (14.98 ± 1.54 to 13.66 ± 1.34, p=0.00116). L-IADL scores also showed more improvement in Group A (7.54 to 11.23, p<0.0001) versus Group B (5.51 to 7.35, p=0.001). A statistically significant improvement was seen (p<0.0001) for both outcome measures post-intervention. Conclusion A superior efficacy was demonstrated by the multimodal exercise program demonstrated in reducing CIPN symptoms and improving functional outcomes compared to standard physical therapy. These findings suggest that comprehensive, multimodal exercise interventions may be more effective in managing CIPN and enhancing quality of life for cancer patients undergoing neurotoxic chemotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。